Knowledge and practices regarding prostate cancer screening in Spanish men: The importance of personal and clinical characteristics (PROSHADE study).


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 29 02 2024
accepted: 21 04 2024
medline: 30 5 2024
pubmed: 30 5 2024
entrez: 30 5 2024
Statut: epublish

Résumé

Patients' decisions on prostate cancer (PCa) opportunistic screening may vary. This study aimed to assess how demographic and health-related characteristics may influence knowledge and decisions regarding PCa screening. A cross-sectional survey was conducted among men aged over 40, randomly sampled from the Spanish population, 2022. The survey underwent development and content validation using a modified Delphi method and was administered via telephone. Binomial logistic regression was used to explore the relationship between respondents' characteristics and participants' knowledge and practices concerning PCa and the PSA test. Out of 1,334 men, 1,067 (80%) respondents were interviewed with a mean age of 58.6 years (sd 11.9). Most had secondary or university studies (787, 73.8%) and 61 (5.7%) self-reported their health status as bad or very bad. Most of the respondents (1,018, 95.4%) had knowledge regarding PCa with nearly 70% expressed significant concern about its potential development (720, 70.8%), particularly among those under 64 years (p = 0.001). Out of 847 respondents, 573 (67.7%) reported that they have knowledge regarding the PSA test: 374 (65.4%) reported receiving information from a clinicians, 324 (86.6%) information about the benefits of the test and 189 (49,5%) about its risks, with differences based on educational background. In a multivariable analysis (adjusted for age, educational level and previous prostate problems), respondents with higher levels of education were more likely to have higher knowledge regarding the PSA test (OR 1.75, 95%CI 1.24-2.50, p<0.001). Although most of the patients reported to have knowledge regarding PCa, half of the interviewed men reported knowledge about PSA test. Differences in knowledge prostate cancer screening and undesirable consequences highlight the need to develop and provide tailored information for patients.

Identifiants

pubmed: 38814917
doi: 10.1371/journal.pone.0303203
pii: PONE-D-24-07506
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0303203

Informations de copyright

Copyright: © 2024 Parker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Lucy A Parker (LA)

Department of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.

Juan-Pablo Caballero-Romeu (JP)

Department of Urology, Dr. Balmis General University Hospital; Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.

Elisa Chilet-Rosell (E)

Department of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.

Ildefonso Hernandez-Aguado (I)

Department of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.

Luis Gómez-Pérez (L)

Department of Urology, University General Hospital of Elche, Elche, Spain.

Pablo Alonso-Coello (P)

Iberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Re-search Institute Sant Pau, Barcelona, Spain.

Ana Cebrián (A)

Cartagena Casco Healthcare Centre, Cartagena, Spain.

Maite López-Garrigós (M)

CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Clinical Laboratory, Hospital Universitario de San Juan, San Juan de Alicante, Spain.

Irene Moral-Pélaez (I)

EAP Sardenya, Barcelona. Institut de Recerca Sant Pau, Barcelona, Spain.

Elena Ronda (E)

CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Public Health Research group, Alicante University, San Vicente del Raspeig, Spain.

Mercedes Gilabert (M)

Department of Health Psychology, Miguel Hernandez University, Elche, Spain.

Carlos Canelo-Aybar (C)

CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.
Iberoamerican Cochrane Centre - Department of Clinical Epidemiology and Public Health, Biomedical Re-search Institute Sant Pau, Barcelona, Spain.

Ignacio Párraga-Martínez (I)

Health Care Center Zone VIII, Servicio de Salud Castilla-La Mancha, Albacete, Spain.

Mª Del Campo-Giménez (M)

Integrated Care Management of Albacete. Health Service of Castilla-La Mancha, Spain.

Blanca Lumbreras (B)

Department of Public Health, History of Science and Gynecology, Miguel Hernandez University, San Juan de Alicante, Spain.
CIBER of Epidemiology and Public Health, CIBERESP, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH